Gingivitis Market

Market Overview:

The 7 major gingivitis markets reached a value of US$ 4.8 Billion in 2023. Looking forward, IMARC Group expects the 7MM to reach US$ 7.27 Billion by 2034, exhibiting a growth rate (CAGR) of 3.85% during 2024-2034.

The gingivitis market has been comprehensively analyzed in IMARC's new report titled "Gingivitis Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Gingivitis refers to a common form of gum disease that involves inflammation of the gums. It is generally caused by the buildup of plaque on teeth, which is a sticky film that appears on teeth when bacteria in the mouth combine with saliva and food particles. Some of the symptoms of the ailment include swollen or tender gums, bleeding gums, especially when brushing or flossing, receding gums, a metallic taste in the mouth, persistent bad breath, changes in the way teeth fit together while chewing or biting, etc. Diagnosing gingivitis typically involves a dental examination and evaluation of symptoms, including red, swollen, or bleeding gums. The dentist will check for signs of inflammation, such as pockets or spaces between the gums and teeth and may use a probe to measure the depth of these spaces. X-rays may also be taken to assess bone loss and other indications of periodontal disease. In some cases, a dental professional might perform a microbial test to identify the specific type of bacteria present in the mouth.

The rising cases of poor oral hygiene leading to plaque buildup on teeth are primarily driving the gingivitis market. Furthermore, the increasing prevalence of several associated factors, such as hormonal changes, smoking, diabetes, medications, genetic predisposition, etc., is also propelling the market growth. Besides this, the widespread adoption of scaling and root planning to remove tartar from below and above the gum line as well as smooth out rough spots on the roots of teeth, is acting as another significant growth-inducing factor. Additionally, the inflating usage of antibiotics, including tetracycline, doxycycline, metronidazole, etc., to kill the bacteria that cause gum disease, thereby reducing inflammation in the gums, is further bolstering the market growth. Apart from this, the escalating demand for enzymatic therapy, since it is a less invasive alternative that uses enzymes to break down plaque and prevent the progression of gingivitis to more severe forms of periodontal disease, is also creating a positive outlook for the market. Moreover, the increasing utilization of laser therapy, which employs a laser to remove infected tissue and promote healing in the gums, is expected to drive the gingivitis market in the coming years.

IMARC Group's new report provides an exhaustive analysis of the gingivitis market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for gingivitis and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the gingivitis market in any manner.

Time Period of the Study

• Base Year: 2023
• Historical Period: 2018-2023
• Market Forecast: 2024-2034

Countries Covered

• United States
• Germany
• France
• United Kingdom
• Italy
• Spain
• Japan
   

Analysis Covered Across Each Country

• Historical, current, and future epidemiology scenario
• Historical, current, and future performance of the gingivitis market
• Historical, current, and future performance of various therapeutic categories in the market
• Sales of various drugs across the gingivitis market
• Reimbursement scenario in the market
• In-market and pipeline drugs

Competitive Landscape:

This report also provides a detailed analysis of the current gingivitis marketed drugs and late-stage pipeline drugs.

In-Market Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance
   

Late-Stage Pipeline Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance
   

*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.

Key Questions Answered in this Report:

Market Insights

• How has the gingivitis market performed so far and how will it perform in the coming years?
• What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
• What was the country-wise size of the gingivitis market across the seven major markets in 2023 and what will it look like in 2034?
• What is the growth rate of the gingivitis market across the seven major markets and what will be the expected growth over the next ten years?
• What are the key unmet needs in the market?
   

Epidemiology Insights

• What is the number of prevalent cases (2018-2034) of gingivitis across the seven major markets?
• What is the number of prevalent cases (2018-2034) of gingivitis by age across the seven major markets?
• What is the number of prevalent cases (2018-2034) of gingivitis by gender across the seven major markets?
• How many patients are diagnosed (2018-2034) with gingivitis across the seven major markets?
• What is the size of the gingivitis patient pool (2018-2023) across the seven major markets?
• What would be the forecasted patient pool (2024-2034) across the seven major markets?
• What are the key factors driving the epidemiological trend of gingivitis?
• What will be the growth rate of patients across the seven major markets?
   

Gingivitis: Current Treatment Scenario, Marketed Drugs and Emerging Therapies

• What are the current marketed drugs and what are their market performance?
• What are the key pipeline drugs and how are they expected to perform in the coming years?
• How safe are the current marketed drugs and what are their efficacies?
• How safe are the late-stage pipeline drugs and what are their efficacies?
• What are the current treatment guidelines for gingivitis drugs across the seven major markets?
• Who are the key companies in the market and what are their market shares?
• What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the gingivitis market?
• What are the key regulatory events related to the gingivitis market?
• What is the structure of clinical trial landscape by status related to the gingivitis market?
• What is the structure of clinical trial landscape by phase related to the gingivitis market?
• What is the structure of clinical trial landscape by route of administration related to the gingivitis market?